Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Condition Directory

Acute Lymphoblastic Leukemia clinical trials

Directory of U.S. ClinicalTrials.gov public records for Acute Lymphoblastic Leukemia. Browse Acute Lymphoblastic Leukemia recruiting trials, filter by phase, sponsor, location, or intervention, and open the official ClinicalTrials.gov study record for each result.

By Clinical Trials Finder Guidance last reviewed June 10, 2026 Data synced October 25, 2026 Report an issue

ClinicalTrials.gov public records Last synced Oct 25, 2026, 10:10 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials
1862
Shown on this page
12
Current sort
Recently updated
Condition scope
Acute Lymphoblastic Leukemia
Additional filters apply within this condition.

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

How Acute Lymphoblastic Leukemia studies are organized in the registry

ALL records split sharply between pediatric and adult populations, so the age filter changes the result set more than for most conditions. Lineage labels (B-cell, T-cell) and immunotherapy platforms such as CAR-T appear in titles and meaningfully narrow the portfolio.

Terms that often appear in related listings
B-cell ALL T-cell ALL pediatric ALL CAR-T

These describe how studies tend to be titled and grouped on ClinicalTrials.gov — they are search vocabulary, not medical guidance.

Filter and sort this condition

These controls apply only within Acute Lymphoblastic Leukemia. Default order is Recently updated. Add location, sponsor, treatment, or recruitment status to narrow this condition page further.

Reset condition filters
Clear filters
Showing 49–60 of 1,862 matching trials for Acute Lymphoblastic Leukemia.
Live ClinicalTrials.gov results.
Local aggregate panels are unavailable or hidden for filtered views. The result list above identifies its data source.

Live official records

Open in full search
Recruiting Phase 2 Interventional

Intrathecal Chemoprophylaxis to Prevent Neurotoxicity Associated With Blinatumomab Therapy for Acute Lymphoblastic Leukemia

NCT05519579
View directory record Official record
Conditions
Acute Lymphoblastic Leukemia
Interventions
Methotrexate, Blinatumomab
Drug
Lead sponsor
Northside Hospital, Inc.
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Oct 14, 2026 · Synced Oct 25, 2026, 10:10 AM EDT
Recruiting Phase 3 Interventional

Single-arm Study of IgPro20 in Adults With Secondary Immune Deficiencies Due to Hematologic Malignancies Treated With B-cell Targeting Chimeric Antigen Receptor T-cell and T-cell Redirecting Therapies

NCT07648264
View directory record Official record
Conditions
Secondary Immune Deficiency
Interventions
IgPro20
Biological
Lead sponsor
CSL Behring
Industry
Eligibility
18 Years and older
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
17
States / cities
Orange, California • Denver, Colorado • Coral Springs, Florida + 14 more
Source: ClinicalTrials.gov public record
Updated Oct 14, 2026 · Synced Oct 25, 2026, 10:10 AM EDT
Recruiting Phase 2 Interventional

Ruxolitinib With Tacrolimus and Methotrexate for the Prevention of Graft Versus Host Disease in Pediatric and Young Adult Patients Undergoing Allogeneic Hematopoietic Cell Transplant for Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, or Myelodysplastic Syndrome

NCT06128070
View directory record Official record
Conditions
Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Myelodysplastic Syndrome
Interventions
Biospecimen Collection, Chest Computed Tomography, Echocardiography, Hematopoietic Cell Transplantation, Methotrexate, Multigated Acquisition Scan, Ruxolitinib Phosphate, Tacrolimus
Procedure · Drug
Lead sponsor
City of Hope Medical Center
Other
Eligibility
2 Years to 22 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2030
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Oct 14, 2026 · Synced Oct 25, 2026, 10:10 AM EDT
Active, not recruiting Phase 2 Interventional

Adding Itacitinib to Cyclophosphamide and Tacrolimus for the Prevention of Graft Versus Host Disease in Patients Undergoing Hematopoietic Stem Cell Transplants

NCT05364762
View directory record Official record
Conditions
Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia, Myelodysplastic Syndrome, Myeloproliferative Neoplasm, Primary Myelofibrosis, Secondary Myelofibrosis
Interventions
Cyclophosphamide, Itacitinib, Peripheral Blood Stem Cell Transplantation, Quality-of-Life Assessment, Tacrolimus
Drug · Procedure · Other
Lead sponsor
City of Hope Medical Center
Other
Eligibility
Up to 80 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Oct 14, 2026 · Synced Oct 25, 2026, 10:10 AM EDT
Not yet recruiting Phase 2 Interventional

CD34+ Transplants for Myeloid Malignancies

NCT05565105
View directory record Official record
Conditions
Leukemia, Myeloid, Acute, Leukemia, Lymphocytic, Acute
Interventions
Busulfan, Melphalan, Fludarabine, CD34+ Allogeneic Peripheral Blood Stem Cell Transplant
Drug · Procedure
Lead sponsor
Guenther Koehne
Other
Eligibility
18 Years to 70 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2027 – 2034
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Oct 25, 2026, 10:10 AM EDT
Recruiting Phase 1Phase 2 Interventional

AZD0486 as Monotherapy in B-cell Acute Lymphoblastic Leukaemia

NCT06137118
View directory record Official record
Conditions
B-cell Acute Lymphoblastic Leukemia (B-ALL)
Interventions
Surovatamig
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
12 Years and older
Enrollment
255 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
12
States / cities
Birmingham, Alabama • Duarte, California • Los Angeles, California + 9 more
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Oct 25, 2026, 10:10 AM EDT
Recruiting Phase 2 Interventional

Asparaginase Erwinia Chrysanthemi With Chemotherapy for the Treatment of High-Risk Adults With Newly Diagnosed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma

NCT06918431
View directory record Official record
Conditions
B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative, Lymphoblastic Lymphoma
Interventions
Asparaginase Erwinia chrysanthemi, Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Computed Tomography, Cyclophosphamide, Cytarabine, Daunorubicin Hydrochloride, Dexamethasone, Echocardiography, Lumbar Puncture, Mercaptopurine, Methotrexate, Positron Emission Tomography, Rituximab, Vincristine Sulfate
Drug · Procedure · Biological
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years to 54 Years
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
8
States / cities
Phoenix, Arizona • Duarte, California • Irvine, California + 5 more
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Oct 25, 2026, 10:10 AM EDT
Recruiting Phase 1Phase 2 Interventional

Phase I/II Study of the Combination of Blinatumomab and Asciminib in Patients With Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia

NCT06308588
View directory record Official record
Conditions
Philadelphia Chromosome-Positive, Acute Lymphoblastic Leukemia
Interventions
Blinatumomab, Asciminib
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
2
States / cities
The Bronx, New York • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Oct 25, 2026, 10:10 AM EDT
Not yet recruiting Phase 1 Interventional

BLinatumomab and iNKT in Relapsed B-Cell ALL

NCT07869368
View directory record Official record
Conditions
B-Cell ALL, ALL (Acute B-Lymphoblastic Leukemia), Philadelphia Chromosome-Negative Lymphoblastic Leukemia, CD19-positive B-cell Acute
Interventions
Invariant Natural Killer T Cell Therapy
Biological
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Oct 9, 2026 · Synced Oct 25, 2026, 10:10 AM EDT
Recruiting No phase listed Observational

Whole Genome Sequencing (ChromoSeq®) for Acute Lymphoblastic Leukemia (ALL) Patients

NCT07313592
View directory record Official record
Conditions
Acute Lymphoblastic Leukemia
Interventions
Not listed
Lead sponsor
Washington University School of Medicine
Other
Eligibility
Up to 30 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Oct 9, 2026 · Synced Oct 25, 2026, 10:10 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Culturally Adapted Parenting Intervention for Spanish-Speaking Parents in Improving Outcomes of Younger Acute Lymphoblastic Leukemia or Acute Myeloid Leukemia Survivors at Risk for Late Neurocognitive Effects

NCT02559557
View directory record Official record
Conditions
Cancer Survivor, Childhood Acute Lymphoblastic Leukemia in Remission, Childhood Acute Myeloid Leukemia in Remission, Cognitive Side Effects of Cancer Therapy
Interventions
Educational Intervention, Quality-of-Life Assessment, Questionnaire Administration
Other
Lead sponsor
City of Hope Medical Center
Other
Eligibility
Not listed
Enrollment
38 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Oct 9, 2026 · Synced Oct 25, 2026, 10:10 AM EDT
Recruiting Phase 1 Interventional

A Study of CD19 Targeted CAR T Cell Therapy in Pediatric Patients With Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia (B ALL) and Aggressive Mature B-cell Non-Hodgkin Lymphoma (B NHL)

NCT06173518
View directory record Official record
Conditions
Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia, Relapsed or Refractory B Cell Non-Hodgkin Lymphoma
Interventions
AUTO1
Biological
Lead sponsor
Autolus Limited
Industry
Eligibility
0 Years to 18 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
9
States / cities
Los Angeles, California • Palo Alto, California • Aurora, Colorado + 6 more
Source: ClinicalTrials.gov public record
Updated Oct 9, 2026 · Synced Oct 25, 2026, 10:10 AM EDT

About this Acute Lymphoblastic Leukemia clinical trials directory page

What this page lists
U.S. ClinicalTrials.gov public records that list Acute Lymphoblastic Leukemia as a study condition, including recruiting, not yet recruiting, and active not recruiting trials across phase 1, phase 2, and phase 3.
How to narrow results
Use the filters above to scope by intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, age, or NCT ID within Acute Lymphoblastic Leukemia.
Where the data comes from
Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, ranking of trials by quality, or AI-generated medical summaries.

Related: all condition pages, browse by drug or therapy, browse by U.S. city, browse by sponsor, or open the full search for Acute Lymphoblastic Leukemia.